NCT05000970

Brief Summary

Emergency patients often have uncontrolled asymptomatic hypertension upon discharge from the emergency department. This 3-arm randomized controlled trial will evaluate the impact of nurse telehealth encounters and remote patient monitoring, using a software called Vital Tech, on blood pressure control and primary care engagement.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
48

participants targeted

Target at P25-P50 for not_applicable hypertension

Timeline
Completed

Started Jul 2021

Typical duration for not_applicable hypertension

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 28, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

July 12, 2021

Completed
1 month until next milestone

First Posted

Study publicly available on registry

August 11, 2021

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2024

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2024

Completed
Last Updated

May 1, 2023

Status Verified

April 1, 2023

Enrollment Period

2.5 years

First QC Date

April 28, 2021

Last Update Submit

April 27, 2023

Conditions

Keywords

Asymptomatic hypertensionReferralTelehealthRemote patient monitoringEmergency Departmentblood pressure

Outcome Measures

Primary Outcomes (6)

  • Recruitment rate

    recruitment rate of patients enrolled in TRIO at 6-months.

    6 months

  • Recruitment rate

    recruitment rate of patients enrolled in TRIO at 12-months.

    12 months

  • Retention rate

    retention rate of patients enrolled in TRIO at 6-months.

    6 months

  • Retention rate

    retention rate of patients enrolled in TRIO at 12-months.

    12 months

  • Attrition rate

    attrition rate of patients enrolled in TRIO at 6-months.

    6 months

  • Attrition rate

    attrition rate of patients enrolled in TRIO at 12-months.

    12 months

Secondary Outcomes (4)

  • Blood pressure

    6 months

  • Blood pressure

    12 months

  • Number of participant who had follow up care

    6 months

  • Number of participant who had follow up care

    12 months

Study Arms (3)

TRIO PLUS tablet and nurse at day 3

EXPERIMENTAL

Virtual nurse encounter at 3 days

Device: blood pressure cuff PLUS tabletOther: Telehealth Consult

TRIO PLUS Tablet and nurse at day 3 and 7

EXPERIMENTAL

Virtual nurse encounter at 3 days and 7 days

Device: blood pressure cuff PLUS tabletOther: Telehealth Consult

TRIO PLUS Group

PLACEBO COMPARATOR

No encounter

Device: blood pressure cuff PLUS tablet

Interventions

all arms

Also known as: wireless BP monitor and tablet
TRIO PLUS GroupTRIO PLUS Tablet and nurse at day 3 and 7TRIO PLUS tablet and nurse at day 3

Telehealth consult with an RN

TRIO PLUS Tablet and nurse at day 3 and 7TRIO PLUS tablet and nurse at day 3

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18 years
  • At least two\* high blood pressure readings during ED visit
  • Systolic (top #) ≥140, ≤180 AND/OR
  • Diastolic (bottom #) ≥ 90, ≤120

You may not qualify if:

  • symptomatic hypertension

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mount Sinai Hospital Center Emergency Dept

New York, New York, 10029, United States

Location

MeSH Terms

Conditions

HypertensionEmergencies

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular DiseasesDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Kimberly Souffront, PhD, APRN

    Icahn School of Medicine at Mount Sinai

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Masking Details
Both participant and investigator will be blinded on the study assignment group.
Purpose
PREVENTION
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 28, 2021

First Posted

August 11, 2021

Study Start

July 12, 2021

Primary Completion

January 1, 2024

Study Completion

April 1, 2024

Last Updated

May 1, 2023

Record last verified: 2023-04

Data Sharing

IPD Sharing
Will not share

Locations